| abstract |
Cell-permeable iron chelators are used to treat solid cancer tumor patients, optionally in combination with autophagy inhibitors. Preferred chelating agents are alkyl substituted N- (1-pyridin-2-yl-methylidene) -N- (9H-1,3,4,9-tetraaza-fluoren-2-yl) -hydrazine. Preferred autophagy inhibitors are chloroquine. In addition, pharmaceutical compositions comprising iron chelating agents, pharmaceutically acceptable carriers, and optionally autophagy inhibitors; And a method of treating cancer by administering an iron chelating agent or a combination of iron chelating agent and autophagy inhibitor in an amount (s) effective to attack the cancer. |